Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab plus first-line chemotherapy in advanced NSCLC
2013-003156-21Phase 3Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of denosumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Overall survival. Started May 2014; status: completed.
02
Drugs
denosumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2013-003156-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003156-21.